Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RApsody: CHS-0214 versus Enbrel in rheumatoid arthritis
2014-000443-33Phase 3Completed
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CHS-0214 + methotrexate with Enbrel + methotrexate (2 arms). Primary endpoint: ACR20 response at Week 24. Started Jun 2014; status: completed.
02
Drugs
GP2015etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-000443-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000443-33.